ftInvstr
SHILPAMED · Healthcare ₹958.0 -0.21% Mkt Cap ₹18694 Cr

SHILPAMED

Healthcare Drug Manufacturers - Specialty & Generic
₹958.0
-0.21% today · 30d +29.87%
as of 2026-09-04
Price · Daily Candles
“Shilpa Medicare: Quarterly Profits Surge 40% as FII and DII Holdings Creep Up”
Shilpa Medicare reported a robust quarter, with net profit surging 40.26% YoY to ₹45 crore and revenue climbing 28.31% YoY to ₹410 crore in Q4 2025. Despite this, its TTM PE of 40.55 stands relatively high compared to some peers like Dr. Reddy's at 19.55, while its ROCE of 8.0% trails the sector average significantly, raising questions about capital efficiency.
BULL CASE
+Net profit saw a significant increase of 40.26% YoY, reaching ₹45 crore in Q4 2025.
+Quarterly revenue grew by 28.31% YoY to ₹410 crore in Q4 2025, demonstrating strong top-line expansion.
+Operating profit increased by 40.69% YoY in Q4 2025, alongside an OPM growth of 2.51%.
+FIIs increased their stake by 0.11% and DIIs by 0.25% QoQ in the quarter ending March 2026.
BEAR CASE
Shilpa Medicare's TTM PE of 40.55 is significantly higher than peers like Dr. Reddy's at 19.55 and Cipla at 29.52.
The 8.0% ROCE is substantially lower than larger peers, with Divi's Lab at 21.47% and Sun Pharma at 22.46%.
Public shareholding decreased by 0.35% QoQ in March 2026.
The company's FCF yield is negative at -1.13%, indicating current free cash flow negativity.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-03-31
REVENUE
₹437 Cr
+32.1% YoY
NET PROFIT
₹108 Cr
+642.91% YoY
OPM
27.67%
+2.74pp YoY
EPS
₹5.51
PE 40.55
Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-0.2% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.
◇ Sector Position
Shilpa Medicare's TTM PE of 40.55 is higher than industrial giants like Sun Pharma (40.41) yet its ROCE of 8.0% lags significantly behind the sector, where peers like Cipla boast a 25.09% ROCE.
PEERPEROCE %
SHILPAMED40.558.0
SUNPHARMA40.4122.46
DIVISLAB69.8121.47
CIPLA29.5225.09
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
68
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 100
Valuation FAIR 40
Growth STRONG 77
Profitability HIGH 75
Technicals NEUTRAL 68
Risk MODERATE 50
Key Stats
TTM PE
40.55
P/B
4.06
52W HIGH
₹973.9
OFF HIGH
-1.63%
DIV YIELD
0.1%
MKT CAP
₹18694 Cr
◉ Active Signals
MACDBullish4.2496
RSI(14)Bearish73.69
Near 52W HighBullish-1.63
Street Consensus
2 analysts
₹517.0
mean target
Low ₹434.0Now ₹958.0High ₹600.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold SHILPAMED and at what entry.

Sign up freeSign in